Welcome to our dedicated page for Dalrada Financl news (Ticker: DFCO), a resource for investors and traders seeking the latest updates and insights on Dalrada Financl stock.
Dalrada Technology Group, Inc., formerly Dalrada Financial Corporation, reports developments tied to its role as a multinational holding company focused on technology, health care, and environmental sustainability. Company news has covered the completed name and ticker change, clean-energy heat pump activity, semiconductor deposition products, specialty pharmacy services, and governance updates.
Recurring operating themes include Dalrada Climate Technology heat pump and energy-sustainability systems for industrial and residential uses, Deposition Technology thin-film deposition and plasma spectroscopy products for semiconductor and related markets, and Genefic Specialty Pharmacy prescription, specialty pharmacy, patient advocacy, and support services. Updates also address facilities, customer contracts, board and officer appointments, audit matters, and capital-structure disclosures.
Dalrada Financial Corp. (OTCQB: DFCO) announces the appointment of Anthony Zolezzi to its Board of Directors. Zolezzi, known for his commitment to sustainability, aims to enhance Dalrada's green energy initiatives. He has a proven track record with ventures like Bubba Gump Shrimp Co. and partnerships with major brands like Walmart and PepsiCo. His experience includes promoting organic agriculture and recycling projects. CEO Brian Bonar emphasizes that Zolezzi's expertise will be vital for furthering the company's sustainability goals amid growing climate change concerns.
Dalrada Financial Corp. (OTCQB: DFCO) announced the acquisition of Pacific Stem Cells, LLC, enhancing its healthcare offerings with non-invasive therapies. This strategic move is anticipated to boost Dalrada's annualized revenue by $2.5MM over the next year. Pacific Stem Cells, recognized for its high-quality regenerative treatments, aims to address various medical conditions, including those related to aging and COVID-19. The global stem cells market is projected to reach USD 17.9 billion by 2027, presenting significant growth potential for Dalrada Health Products.
Dalrada Financial Corp. (OTCQB: DFCO) announced its acquisition of International Health Group, Inc. (IHG), a healthcare training organization. This acquisition aims to enhance healthcare staffing, especially for COVID-19 vaccination efforts in Southern California. IHG, which has trained nearly 7,000 medical professionals since 2006, is projected to generate $1MM in annual revenue within a year. CEO Brian Bonar highlighted the strategic significance of this acquisition for staffing solutions in nursing and home health. With the U.S. healthcare staffing market valued at $17 billion, this move positions Dalrada for substantial growth.
Dalrada Financial Corp. (OTC Pink: DFCO) reported a remarkable growth of 1,532% in total revenues for the fiscal year ending June 30, 2020, achieving $1,178,154 in revenues compared to $72,155 in 2019. Gross profits also rose to $552,238. The surge in performance is attributed to sales of GlanHealth's sanitizing products, Prakat Solutions' expansion in software development, and new orders from Dalrada Precision. The company aims to enhance transparency by filing periodic reports with the SEC.
Dalrada Financial Corp. (OTC Pink: DFCO) has announced that its subsidiary, Dalrada Precision, acquired a license for a green energy generator with 87% efficiency. This technology aims to meet the rising demand for affordable, clean energy. It's anticipated that integrating this generator with Likido Limited could enhance energy savings by up to $110,000 annually for a 250-room hotel. The project is currently undergoing analysis for cost modeling and manufacturing, which could significantly boost Dalrada's market position in sustainable energy solutions.
Dalrada Financial Corp. (OTC Pink: DFCO) reports a remarkable 1,602% increase in total revenues, reaching $1,228,604 for the fiscal year ending June 30, 2020, compared to $72,155 in 2019. The gross profit margin stands at 43%. However, the company incurs a net loss due to higher research and development costs and capital expenditures. Q4 2020 revenues are reported at $827,797, up from $351,324 in Q3. Growth is attributed to GlanHealth's sanitizing products and Prakat Solutions' business expansion.